Director Gary Pace Buys $1M of Cardiff Oncology Stock at $1.46, Adding to Position Amid Cash Crunch
CRDF is trading near its 52-week low of $0.83 (10% above the low).
Summary
Director Gary Pace bought $1 million of Cardiff Oncology stock at $1.46 per share, a 1.67% stake increase, signaling confidence amid a cash crunch and license dispute.
Key Events · Ownership and Investor Activity · CRDF
-
Director Buys $1M in Open Market
Gary Pace acquired 1,374,570 shares at $1.46 each, totaling $1,000,000, increasing his direct holdings to 2,043,661 shares.
-
Warrants Add Potential Upside
Pace also received 687,285 warrants with a $1.33 exercise price, exercisable after six months or upon authorized share increase, expiring 5.5 years later.
-
Purchase Follows Recent Financing
The buy comes two days after Cardiff Oncology raised $10.05M in a registered direct offering at $1.05/share, with insider participation.
-
Backdrop of Going Concern and License Dispute
The company faces a short cash runway into Q1 2027 and a terminated license agreement for its lead drug onvansertib, despite positive Phase 2 data.
Analysis · CRDF · Life Sciences
On July 14, director Gary Pace demonstrated a strong vote of confidence by purchasing $1 million worth of Cardiff Oncology shares at $1.46 per share. The transaction occurred just two days after the company raised $10.05 million in a registered direct offering priced at $1.05 per share, and against a backdrop that includes a going concern warning and a critical license dispute for its lead drug onvansertib. Pace also received warrants to buy an additional 687,285 shares at $1.33, exercisable after six months or upon shareholder approval of an authorized share increase. If exercised, the total potential dilution from the warrants would be substantial relative to the company's micro-cap size, yet the open-market purchase signals conviction in the company's prospects despite near-term liquidity risks.
How filings like this one have moved
In the 30 days to Sep 14, 2026, 35.8% of the 1045 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.43%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CRDF was trading at $0.92 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $59.8M. The 52-week trading range was $0.83 to $4.56. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.